LONDON (Thomson Financial) - Melior Discovery, Inc. announced today that it
has signed an option agreement that provides Pfizer Inc. the exclusive right to
negotiate a license to MLR-1023, Melior's drug candidate for Type II diabetes.
In exchange, Pfizer agreed to make an undisclosed payment to Melior and
provide access to certain data it owns related to MLR-1023. In addition, Melior
agreed to utilize its in-vivo theraTRACE indications discovery platform to
evaluate the activity of selected Pfizer compounds in partnership with Pfizer.
"This is the second collaboration initiated with Pfizer in the last 18
months and we look forward to this expansion to our productive research and
development relationship," said Andrew Reaume President and CEO of Melior.
tf.TFN-Europe_newsdesk@thomson.com
lam/lam
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|